GBA Gene Mutations and Parkinson's Disease Risk

GBA Gene Mutations and Parkinson's Disease Risk

Overview

The glucocerebrosidase (GBA) gene represents the most significant genetic risk factor for Parkinson's disease (PD) identified to date [PMID: 19794875]. Homozygous or compound heterozygous mutations in GBA cause Gaucher disease, a lysosomal storage disorder, while heterozygous mutations confer a substantial increase in PD risk [PMID: 15578416]. This mechanism page explores the molecular, cellular, and clinical implications of GBA mutations in Parkinson's disease pathogenesis.

The discovery of the GBA-PD association has transformed our understanding of the shared pathophysiology between lysosomal storage disorders and neurodegenerative diseases [PMID: 28447057]. This connection has opened new therapeutic avenues targeting lysosomal function and glucocerebrosidase activity in PD [PMID: 29198438].

Pathway Diagram

GBA Gene Mutations and Parkinson's Disease Risk

Overview

The glucocerebrosidase (GBA) gene represents the most significant genetic risk factor for Parkinson's disease (PD) identified to date [PMID: 19794875]. Homozygous or compound heterozygous mutations in GBA cause Gaucher disease, a lysosomal storage disorder, while heterozygous mutations confer a substantial increase in PD risk [PMID: 15578416]. This mechanism page explores the molecular, cellular, and clinical implications of GBA mutations in Parkinson's disease pathogenesis.

The discovery of the GBA-PD association has transformed our understanding of the shared pathophysiology between lysosomal storage disorders and neurodegenerative diseases [PMID: 28447057]. This connection has opened new therapeutic avenues targeting lysosomal function and glucocerebrosidase activity in PD [PMID: 29198438].

Pathway Diagram

The GBA Gene and Protein

Gene Structure

The GBA gene is located on chromosome 1q21 and spans approximately 7.5 kb [PMID: 2362523]. It consists of 11 exons encoding a 497-amino acid protein. The gene is in close proximity to a highly similar pseudogene (GBAP1) on the same chromosome, which complicates genetic analysis due to recombination events and gene conversions that can create hybrid alleles [PMID: 31801877].

Protein Function

Glucocerebrosidase (GCase) is a lysosomal hydrolase that catalyzes the hydrolysis of glucosylceramide (GlcCer) to glucose and ceramide [PMID: 7543674]. The enzyme operates optimally at acidic pH (4.5-5.0) within lysosomes and requires co-factors including saposin C and the lysosomal membrane protein LIMP-2 for proper function and trafficking [PMID: 24204708].

| Property | Description |
|----------|-------------|
| Molecular weight | 55.8 kDa (precursor), 50.8 kDa (mature) |
| Cellular localization | Lysosome |
| Tissue expression | Highest in spleen, liver, kidney; moderate in brain |
| Substrate preference | Glucosylceramide, glucosylsphingosine |
| Cofactors | Saposin C, LIMP-2 |

GBA Mutations in Gaucher Disease

Types of Mutations

Over 400 GBA mutations have been identified in patients with Gaucher disease [PMID: 35210328]. These include:

• Missense mutations: N370S, L444P, V394L, D409H
• Splice-site mutations: IVS2+1, IVS10-1
• Recombinant alleles: Complex mutations from gene conversion with GBAP1
• Null mutations: Frameshift, nonsense mutations causing complete loss of function

Gaucher Disease Types

| Type | Phenotype | GBA Mutations | Notes |
|------|-----------|---------------|-------|
| Type 1 | Non-neuronopathic | N370S, other mild mutations | Most common form |
| Type 2 | Acute neuronopathic | L444P, D409H | Fatal in early childhood |
| Type 3 | Chronic neuronopathic | L444P, other combinations | Progressive neuro degeneration |

GBA and Parkinson's Disease Risk

Epidemiology

Multiple large-scale studies have established the association between GBA mutations and PD risk [PMID: 19794875]:

| Study | Population | Odds Ratio (Heterozygotes) |
|-------|------------|---------------------------|
| Aharon-Peretz et al. 2004 | Ashkenazi Jewish | 7.9 |
| Sidransky et al. 2009 | Multi-center | 5.0 |
| Li et al. 2019 (Meta-analysis) | Global | 4.5 |
| Lee et al. 2022 | East Asian | 4.2 |
| Pitsi et al. 2022 (Meta-analysis) | Global | 4.3 |

The lifetime risk of PD in GBA mutation carriers is estimated at 20-30%, compared to 1-2% in the general population [PMID: 35193376].

Common Risk-Associated Mutations

Not all GBA mutations confer equal PD risk. Studies have stratified mutations into [PMID: 31932556]:

• High-risk mutations: N370S, L444P, RecNcil, RecTL (odds ratio 4-8)
• Low-risk mutations: E326K, T369M (odds ratio 1.5-2.5)
• Protective variants: p.E427K (reduces risk by 50%) [PMID: 34758327]

Mechanisms of Pathogenesis

1. Lysosomal Dysfunction

Reduced GCase Activity

GBA mutations lead to decreased GCase activity in lysosomes, impairing the degradation of glucosylceramide and glucosylsphingosine [PMID: 21518790]. This results in:

• Substrate accumulation in lysosomes
• Disruption of autophagic flux
• Impaired cellular clearance mechanisms
• Increased lysosomal membrane permeability [PMID: 33249484]
• Lysosomal membrane permeabilization triggers mitochondrial dysfunction [PMID: 33984187]
• Activation of inflammasome and neuroinflammation [PMID: 32893341]

Impact on Alpha-Synuclein Degradation

GCase deficiency impairs the degradation of α-synuclein through multiple pathways [PMID: 21857691]:

• Direct competition for lysosomal degradation
• Impaired autophagosome-lysosome fusion
• Reduced activity of cathepsins involved in α-synuclein cleavage
• Accumulation of toxic oligomeric species [PMID: 30189854]
• The bidirectional relationship creates a pathogenic feedback loop [PMID: 21782287]

2. Endoplasmic Reticulum Stress

Misfolding and ER Retention

Many GBA mutations result in misfolded protein that is retained in the endoplasmic reticulum and targeted for degradation [PMID: 33984187]. This leads to:

• Activation of unfolded protein response (UPR)
• Increased ER stress markers (BiP, CHOP, XBP1s)
• Impaired cellular proteostasis
• Pro-apoptotic signaling
• Calcium homeostasis disruption

ER-Lysosome Communication

ER stress disrupts calcium homeostasis and impairs the function of the ER, affecting lysosomal biogenesis and function through disrupted mTORC1 signaling and TFEB activation [PMID: 28545462].

3. Mitochondrial Dysfunction

The GBA-pathogenesis cascade intersects with mitochondrial function through multiple mechanisms [PMID: 23089147]:

• Lysosomal dysfunction leads to impaired mitophagy
• Accumulation of damaged mitochondria
• Reduced ATP production
• Increased reactive oxygen species (ROS) production
• Loss of mitochondrial membrane potential

4. Neuroinflammation

Neuroinflammation is a key feature of GBA-PD pathogenesis [PMID: 32893341]:

• Activated microglia surrounding GCase-deficient neurons
• Increased pro-inflammatory cytokines (IL-1β, TNF-α, IL-6)
• Complement system activation
• NLRP3 inflammasome activation
• Peripheral immune cell infiltration

Clinical Phenotype of GBA-PD

Motor Symptoms

GBA-PD patients present with typical PD motor symptoms but often show earlier onset [PMID: 26781774]:

• Mean age at onset: 56-58 years (vs. 60-62 years in idiopathic PD)
• More severe motor symptoms (higher UPDRS scores)
• Greater levodopa requirement
• More frequent motor fluctuations
• Earlier onset of dyskinesias

Non-Motor Symptoms

Cognitive Impairment and Dementia

Cognitive impairment is more prevalent and severe in GBA-PD [PMID: 25042937]:

• Higher risk of developing dementia (HR 2.1-3.5)
• Earlier onset of cognitive decline
• More rapid progression
• Higher prevalence of visual hallucinations
• Diffuse cortical and subcortical atrophy

Other Non-Motor Features

• Autonomic dysfunction: Earlier and more severe orthostatic hypotension
• Sleep disorders: Higher prevalence of REM sleep behavior disorder
• Psychiatric manifestations: More frequent depression and anxiety
• Hyposmia: Similar prevalence to idiopathic PD

Neuropathology

The neuropathological features of GBA-PD include [PMID: 32064597]:

• Widespread Lewy body pathology (Braak stages 5-6)
• Higher burden of α-synuclein pathology
• More frequent cortical Lewy bodies
• Variable tau pathology
• Less prominent Lewy body morphology

Biomarkers

Fluid Biomarkers

Glucosylsphingosine (Lyso-Gb1)

Glucosylsphingosine (Lyso-Gb1) is a sensitive biomarker for GBA mutation status and disease progression [PMID: 33249484]:

• Elevated in GBA mutation carriers (10-100x normal)
• Correlates with disease severity
• Tracks with clinical progression
• Useful for therapeutic monitoring

Other CSF Biomarkers

• Total tau and phosphorylated tau
• α-synuclein seeding activity
• Neurofilament light chain (NfL)
• Inflammatory markers

Genetic Biomarkers

• Specific GBA mutation status
• GBA variant modifiers (PSAP, SMPD1)
• Polygenic risk scores

Therapeutic Approaches

Disease-Modifying Therapies

GCase Modulators

Ambroxol: A pharmacological chaperone that increases GCase activity [PMID: 35210329]

• Phase 2 clinical trial completed
• Increases GCase activity and reduces glucosylsphingosine
• May reduce α-synuclein burden
• Currently in Phase 2b/3 trials

Substrate Reduction Therapy

Inhibiting glucosylceramide synthase to reduce substrate accumulation [PMID: 24243067]:

• Eliglustat tartrate and similar compounds
• Reduces glucosylceramide and glucosylsphingosine
• Potential to slow disease progression

Gene Therapy

• AAV-vector delivered GBA
• CRISPR-based gene editing approaches
• LIMP-2 targeted therapies [PMID: 30189854]

Symptomatic Treatments

Standard PD treatments remain effective but require careful management:

• Levodopa/carbidopa
• Dopamine agonists
• MAO-B inhibitors
• Deep brain stimulation (earlier consideration due to faster progression)

Animal Models

Mouse Models

Several GBA mouse models have been developed:

• Conditional knockout mice: Neuron-specific GBA deletion
• Point mutation models: N370S and L444P knock-in mice
• Dual pathology models: GBA deletion with α-synuclein overexpression

• Reduced GCase activity
• Glucosylceramide accumulation
• α-synuclein pathology
• Neuroinflammation
• Motor and non-motor phenotypes

Induced Pluripotent Stem Cell (iPSC) Models

iPSC-derived neurons from GBA-PD patients show:

• Reduced GCase activity
• Impaired autophagosome-lysosome function
• Increased α-synuclein aggregation
• Mitochondrial dysfunction
• ER stress

Genetic Modifiers and Interaction

Modifier Genes

Several genes modify GBA-PD risk and progression [PMID: 27898198]:

• SMPD1: Acid sphingomyelinase variants affect risk
• PSAP: Prosaposin variants modify severity
• ATP13A2: Lysosomal calcium channel

Polygenic Risk

• GBA mutations interact with overall polygenic risk
• Combined genetic risk scores predict progression
• Family history increases risk in carriers

Related Pages

• [Lysosomal Dysfunction Comparison](./lysosomal_dysfunction_comparison/lysosomal_dysfunction_comparison.md)
• [Protein Aggregation Comparison](./protein_aggregation_comparison/protein_aggregation_comparison.md)
• [Alpha-Synuclein Pathology in PD](./alpha_synuclein_parkinson/alpha-synuclein-pathology.md)
• [Neuroinflammation Mechanisms](./neuroinflammation/neuroinflammation-pd.md)
• [Mitochondrial Dysfunction in PD](./mitochondrial_dysfunction_comparison/parkinsons-mitochondrial.md)

Population Genetics

Ethnic Distribution

The frequency of GBA mutations varies significantly across ethnic populations [PMID: 35210328]:

• Ashkenazi Jewish: Highest carrier frequency (1:15 to 1:20)
• European: Carrier frequency ~1:100 to 1:150
• East Asian: Lower frequency but significant contribution
• African: Rare, limited data available

Genotype-Phenotype Correlation

Different GBA mutations demonstrate distinct patterns of PD risk and progression [PMID: 23625236]:

Severe mutations (L444P, Del55bp, RecNcil):

• Earlier onset of PD (mean 53 years)
• More severe cognitive decline
• Faster progression
• Higher prevalence of dementia

• Later onset (mean 60 years)
• Slower progression
• Less severe cognitive impairment

• Variable phenotype
• Often associated with earlier onset
• Higher risk of dementia

Molecular Mechanisms in Detail

Autophagy-Lysosome Pathway

The autophagy-lysosome pathway is central to GBA-PD pathogenesis [PMID: 30189854]:

Impaired Autophagosome Formation

• GCase deficiency disrupts early stages of autophagy
• Reduced LC3-II conversion
• Impaired nucleation of autophagosomes
• Decreased mitophagy capacity

Lysosomal Membrane Permeabilization

Substrate accumulation causes lysosomal membrane instability [PMID: 33249484]:

• Release of hydrolytic enzymes to cytoplasm
• Activation of apoptotic pathways
• Mitochondrial outer membrane permeabilization
• Release of DAMPs triggering inflammation

TFEB and Mitophagy

TFEB (Transcription Factor EB) dysregulation compounds the problem:

• Impaired lysosomal biogenesis
• Reduced expression of autophagy genes
• Compromised clearance of damaged organelles
• Decreased mitochondrial quality control

Calcium Homeostasis

ER and lysosomal calcium stores are dysregulated in GBA-PD [PMID: 33984187]:

• ER calcium depletion triggers UPR
• Lysosomal calcium release is impaired
• Mitochondrial calcium uptake is altered
• Cellular bioenergetics are compromised
• Calcium-dependent proteases are activated

Lipid Metabolism

GCase deficiency affects cellular lipid homeostasis [PMID: 34758327]:

• Glucosylceramide accumulation in membranes
• Altered membrane fluidity
• Disrupted lipid raft composition
• Impaired signaling through membrane proteins
• Changes in cholesterol distribution

Protein Quality Control

The proteostasis network is overwhelmed in GBA-PD [PMID: 28447057]:

• Ubiquitin-proteasome system impairment
• Increased polyubiquitinated proteins
• Accumulation of misfolded proteins
• Stress granule formation
• Impaired protein turnover

Clinical Management

Diagnosis

Clinical suspicion of GBA-PD should arise in patients with:

• Early-onset PD (<60 years)
• Family history of PD or Gaucher disease
• Ashkenazi Jewish ancestry
• Rapid progression
• Prominent cognitive impairment
• Poor response to standard therapies

Genetic Testing

Genetic counseling is essential for patients and families [PMID: 31801877]:

• Comprehensive GBA sequencing
• Pseudogene analysis
• Confirmation of complex alleles
• Testing family members (with counseling)
• Discussion of reproductive implications

Disease Monitoring

Regular monitoring should include:

• Motor assessment (UPDRS parts I-III)
• Cognitive testing (MoCA, MMSE, neuropsychological battery)
• Autonomic function testing
• Neuroimaging (DAT PET, MRI)
• Fluid biomarker tracking
• Quality of life measures

Management Strategies

Pharmacological

• Levodopa: Gold standard, may need higher doses
• Dopamine agonists: Pramipexole, ropinirole
• MAO-B inhibitors: Selegiline, rasagiline
• COMT inhibitors: For motor fluctuations
• Anticholinergics: Use with caution (cognitive risk)
• Amantadine: For dyskinesias

Non-Pharmacological

• Physical therapy
• Occupational therapy
• Speech therapy
• Cognitive training
• Sleep hygiene
• Dietary modifications

Emerging Therapies in Clinical Trials

Several clinical trials are investigating disease-modifying therapies [PMID: 33840407]:

Active Trials:

• Ambroxol phase 2b/3 (NCT02914366)
• Eliglustat for substrate reduction
• Gene therapy trials (AAV-GBA)
• Antisense oligonucleotides

• Ambroxol phase 2 (NCT02914366)
• Venglustat phase 2 (NCT02023445)
• Lenti-GBA phase 1 (NCT04411654)

Research Directions

Biomarker Development

Key areas of biomarker research include:

• Lyso-Gb1 as predictive biomarker
• α-synuclein seeding assays (RT-QuIC, PMCA)
• Neurofilament light chain
• Imaging biomarkers (DAT PET, neuromelanin MRI)
• Genetic modifiers

Understanding Disease Progression

Research focuses on:

• Natural history studies
• Neuroimaging progression markers
• Fluid biomarker longitudinal studies
• Genotype-phenotype correlations
• Endophenotype identification

Therapeutic Targets

Beyond GCase modulation, targets include:

• α-synuclein aggregation inhibitors
• Autophagy enhancers
• Anti-inflammatory agents
• Mitochondrial protectants
• Calcium stabilizers

Conclusion

The discovery of GBA as the most significant genetic risk factor for PD has opened new avenues for understanding neurodegenerative disease pathogenesis. The bidirectional relationship between GCase dysfunction and α-synuclein pathology creates a feed-forward pathogenic loop that drives disease progression [PMID: 21782287]. Understanding this relationship has led to multiple therapeutic approaches targeting lysosomal function, substrate reduction, and protein homeostasis. As clinical trials progress, GBA-PD represents a model for genetically targeted therapy in neurodegenerative diseases.

Key Takeaways

Future Directions

The field of GBA-PD research continues to evolve with several promising directions: PMID: 19794875

• Precision medicine approaches targeting specific GBA mutations
• Combination therapies addressing multiple pathogenic mechanisms
• Early intervention strategies in pre-symptomatic carriers
• Personalized biomarker panels for risk stratification and monitoring
• International registries to understand natural history and treatment responses

GBA Mutations and Other Neurodegenerative Diseases

Comparison with Gaucher Disease

GBA-PD shares features with neuronopathic Gaucher disease:

Common Pathogenic Mechanisms: Both conditions involve GCase deficiency and consequent lysosomal dysfunction. The degree of enzyme deficiency determines disease severity.

CNS Involvement in Gaucher: Type 2 and type 3 Gaucher disease show neurological involvement, providing insights into GBA-related neurodegeneration.

Relationship with Alzheimer's Disease

GBA mutations may influence AD risk:

Cognitive Decline in GBA-PD: GBA carriers show earlier and more severe cognitive impairment, suggesting shared mechanisms with AD.

GCase and Amyloid: GCase may interact with amyloid processing, though this relationship is less characterized than with α-synuclein.

Therapeutic Development

Pharmacological Chaperones

Small molecules that stabilize mutant GCase:

Ambroxol: This GCase chaperone has shown promise in clinical trials. It increases GCase activity and reduces substrate accumulation. Phase 2 trials in GBA-PD are ongoing.

Other Chaperones: Compound 4, a potent GCase chaperone, is in preclinical development. These compounds must cross the blood-brain barrier for efficacy.

Substrate Reduction Therapy

Reducing glucosylceramide accumulation:

Eliglustat: This FDA-approved Gaucher drug reduces substrate production. It may benefit GBA-PD patients.

GZ/SAR402671: This brain-penetrant substrate reduction therapy is in development for GBA-PD.

Gene Therapy Approaches

Restoring GCase expression:

AAV-GBA: Gene therapy vectors delivering functional GBA are in development. These approaches offer potential for long-term benefit.

CRISPR Editing: Gene editing technologies may correct pathogenic mutations in the future.

Biomarkers for GBA-PD

Glucosylsphingosine (Lyso-Gb1)

This lipid is the key biomarker:

Diagnostic Utility: Elevated Lyso-Gb1 distinguishes GBA carriers from non-carriers. Levels correlate with mutation severity.

Therapeutic Monitoring: Chaperone therapy reduces Lyso-Gb1 levels. This provides a biomarker of treatment response.

GCase Activity

Measuring enzyme function:

Peripheral GCase: Leukocyte GCase activity is reduced in carriers. This provides a functional readout.

Therapeutic Response: GCase activity increases with effective treatment.

Imaging Biomarkers

Neuroimaging markers:

DaTscan: Dopamine transporter imaging shows typical Parkinsonian patterns in GBA-PD.

MRI: White matter changes may be more prominent in GBA carriers.

Clinical Trial Considerations

Patient Selection

Genetic and clinical factors:

Mutation Stratification: Carriers of severe mutations (e.g., L444P) may benefit more from certain therapies. Stratification improves trial efficiency.

Disease Stage: Early-stage patients may benefit most from disease-modifying therapies.

Outcome Measures

Appropriate endpoints:

Motor Symptoms: MDS-UPDRS provides standard motor assessment.

Cognitive Measures: MoCA and comprehensive neuropsychological testing capture cognitive progression.

Biomarker Endpoints: Lyso-Gb1 and GCase activity serve as pharmacodynamic markers.

Research Gaps and Future Directions

Unanswered Questions

Several key questions remain in GBA-PD research:

Mechanism of Risk: The exact mechanism by which GCase deficiency increases PD risk is not fully understood. The bidirectional relationship with α-synuclein is established, but the precise molecular events remain unclear.

Penetrance: Not all GBA mutation carriers develop PD. The modifiers that determine who develops disease are unknown.

Therapeutic Window: The optimal timing for therapeutic intervention is unclear. Pre-symptomatic intervention may be most effective but presents practical challenges.

Emerging Research Areas

New research directions promise to advance the field:

Single-Cell Studies: Single-cell RNA sequencing will clarify cell-type specific effects of GCase deficiency.

iPSC Models: Patient-derived induced pluripotent stem cells provide human disease models.

Protein-Protein Interactions: Understanding GCase's interactome may reveal additional therapeutic targets.

Glycosphingolipidomics: Detailed lipidomics will identify additional biomarker candidates. These comprehensive lipid profiles may reveal new therapeutic targets and disease biomarkers.

International Collaboration: Large-scale collaborative efforts are essential for rare GBA variants. Global registries enable genotype-phenotype correlation studies and clinical trial recruitment.

Machine Learning Applications: AI and machine learning are being applied to GBA-PD research. These tools analyze large datasets to identify predictors of disease progression and treatment response.

Biomarker Validation Studies: Large prospective studies are needed to validate candidate biomarkers. Multi-center collaborations ensure adequate sample sizes and diverse populations.

Neuroimaging Advances: Advanced MRI techniques including neuromelanin imaging and diffusion tensor imaging show promise for detecting early changes in GBA-PD. PET ligands targeting GCase are in development.

Epigenetic Modifications: Research explores whether GBA mutations influence epigenetic regulation. DNA methylation and histone modifications may affect disease expression and progression.

Environmental Interactions: Studies investigate how environmental factors interact with GBA mutations. Pesticide exposure, head trauma, and other factors may modify risk in carriers.

Clinical Implications

The understanding of GBA-PD has several clinical implications:

Genetic Counseling: Family members of patients with GBA-PD should be offered genetic testing and counseling. The variable penetrance of GBA mutations requires careful interpretation of results.

Risk Stratification: Patients with GBA mutations represent a distinct subgroup requiring specialized care. Early identification enables monitoring and potential early intervention.

Therapeutic Considerations: Standard PD therapies remain effective but may require modification. Faster progression suggests earlier consideration of advanced therapies.

Future Therapeutic Targets

Emerging therapeutic approaches target additional mechanisms:

Anti-inflammatory Therapies: Given the prominent neuroinflammation in GBA-PD, anti-inflammatory agents are under investigation. NLRP3 inhibitors show preclinical promise.

Mitochondrial Protectants: Agents protecting mitochondrial function may benefit GBA-PD patients. CoQ10 and related compounds are being studied.

Lipid Modulators: Agents restoring lipid homeostasis may prove beneficial. Targeting glycosphingolipid metabolism addresses the primary defect.

Combination Approaches: Combining multiple therapeutic modalities may prove most effective. Chaperone therapy with substrate reduction represents one promising combination. Page created: 2026-03-25 Last expanded: 2026-03-30 Category: Mechanisms Tags: GBA, glucocerebrosidase, Parkinson's disease, lysosomal storage disorder, Gaucher disease, alpha-synuclein, genetic risk factor

See Also

Related Hypotheses:

• [Multi-Modal CRISPR Platform for Simultaneous Editing and Monitoring](/hypotheses/h-e23f05fb)
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypotheses/h-de0d4364)
• [Purinergic Signaling Polarization Control](/hypotheses/h-0758b337)
• [Mechanosensitive Ion Channel Reprogramming](/hypotheses/h-db6aa4b1)
• [Lipid Droplet Dynamics as Phenotype Switches](/hypotheses/h-7d4a24d3)

• [Validate Mitochondria-Lysosome Contact Site Dysfunction in PD](/experiment/exp-wiki-experiments-mcs-pd-validation)
• [MLCS Quantification in Parkinson's Disease](/experiment/exp-wiki-experiments-mlcs-quantification-parkinsons)
• [LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Never Develop PD](/experiment/exp-wiki-experiments-lrrk2-gba-carrier-resilience-pd)

References